Franck Grimaud

Part of Valneva SE, Valneva UK Ltd. provides health care services. The private company is based in London, UK and was founded in 2015.

Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The private company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013.

Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers.

Part of Valneva SE, Valneva Canada, Inc. engages in marketing and distribution of vaccines. The private company is based in Kirkland, Canada.

Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The private company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014.

Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers.

Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The private company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014.

Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers.

Part of Valneva SE, Valneva Canada, Inc. engages in marketing and distribution of vaccines. The private company is based in Kirkland, Canada.

Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers.

Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The private company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013.

Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The private company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013.

Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The private company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014.

Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The private company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014.

Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers.

Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The private company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013.

Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France.